Shots:

• The NMPA has approved the IND application for the P- III SIENDO trial to evaluate the safety and efficacy of selinexor for advanced or recurrent endometrial cancer. The trial is being conducted over 80 centers across North America- Europe- and Asia and the results are expected in H2’2021
• Antengene holds the exclusive development and commercial rights for the therapy in Asia-Pacific markets and is currently conducting 5 clinical trials of selinexor for the treatment of MM- DLBCL- NSCLC and peripheral T & NK/T-cell lymphoma
• Selinexor is first in class oral selective inhibitor and 1^st FDA-approved drug for use in both MM and DLBCL. The company has submitted NDAs for therapy in Asia Pacific markets

  Ref: PRNewswire | Image: PRNewswire